Posted on 24/08/2010 in Pharmaceutical Company Product News Baxter has agreed a new deal which gives it commercialisation rights to a new therapy for alpha-1 antitrypsin deficiency (AATD) patients.
The company has paid an upfront sum of $20 million (13 million pounds) to secure the rights to Glassia, which is specified for chronic augmentation and maintenance therapy in individuals with emphysema resulting from AATD.
This will see Baxter take over responsibility for manufacturing the drug from its original creator Kamada, which will receive additional payments based on the achievement of commercial milestones.
Larry Guiheen, president of global biopharmaceuticals at Baxter BioScience, said: "The agreement with Kamada underscores Baxter's commitment to expanding the diagnosis of AATD by bringing new and innovative therapeutic options to alpha-1 patients and their treating physicians."
Last month, the pharmaceutical company published its financial results for the second quarter of 2010, during which the firm saw its net sales increase by two per cent year-on-year. Other news stories from 24/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
